Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Sayana Press UK Self-Injection Study

Phase 4

Completed

Conditions: Contraception

Interventions: Drug: Sayana Press

First Posted Date: 2017-01-27

Last Posted Date: 2019-10-18

Lead Sponsor: Pfizer

Target Recruit Count: 169

Registration Number: NCT03034057

Locations: 🇬🇧
Rame Medical Ltd, Penntorr Health, Torpoint, Cornwall, United Kingdom
🇬🇧
Homerton University Hospital NHS Foundation Trust, Homerton, London, United Kingdom
🇬🇧
Southport & Ormskirk Hospital NHS Trust, Liverpool, Merseyside, United Kingdom

and more 22 locations

Post-Marketing Surveillance To Observe Safety And Efficacy Of Xyntha Solofuse Prefilled Syringe

Completed

Conditions: Factor VIII Deficiency, Congenital
Autosomal Hemophilia A
Hemophilia A, Congenital
Factor 8 Deficiency, Congenital
Classic Hemophilia

First Posted Date: 2017-01-27

Last Posted Date: 2023-11-13

Lead Sponsor: Pfizer

Target Recruit Count: 106

Registration Number: NCT03034044

Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies

Phase 3

Completed

Conditions: Osteoarthritis
Cancer Pain
Recurrent Low Back Pain

Interventions: Drug: Investigational medical product (IMP) administered in parent study

First Posted Date: 2017-01-26

Last Posted Date: 2021-06-25

Lead Sponsor: Pfizer

Target Recruit Count: 4

Registration Number: NCT03031938

Locations: 🇺🇸
USC Keck School of Medicine, Los Angeles, California, United States
🇺🇸
Kennedy and White Orthopaedic Center, Sarasota, Florida, United States
🇺🇸
Lafayette Clinical Research Group, Lafayette, Indiana, United States

and more 3 locations

Multiple Ascending Dose and DDI Study

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Placebo
Drug: PF-06835919
Drug: atorvastatin

First Posted Date: 2017-01-25

Last Posted Date: 2017-09-06

Lead Sponsor: Pfizer

Target Recruit Count: 62

Registration Number: NCT03031119

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

Pharmacokinetics, Pharmacodynamics And Safety Study Of Elelyso(tm) In Pediatric Subjects With Type 1 Gaucher Disease

Phase 4

Withdrawn

Conditions: Type 1 Gaucher Disease

Interventions: Drug: Elelyso 60 units/kg

First Posted Date: 2017-01-16

Last Posted Date: 2019-09-24

Lead Sponsor: Pfizer

Registration Number: NCT03021941

Locations: 🇺🇸
O&O Alpan LLC, Fairfax, Virginia, United States

Safety and Tolerability of PF-06818883 in Healthy Subjects

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: Placebo
Drug: PF-06818883

First Posted Date: 2017-01-13

Last Posted Date: 2017-12-11

Lead Sponsor: Pfizer

Target Recruit Count: 30

Registration Number: NCT03020784

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

Prevenar13 Drug Use Investigation - Adults Aged 65 Years or Older-

Completed

Conditions: Adult Not Younger Than 65 Years

First Posted Date: 2017-01-09

Last Posted Date: 2023-09-13

Lead Sponsor: Pfizer

Target Recruit Count: 696

Registration Number: NCT03014206

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis

Phase 1

Completed

Conditions: Lyme Borreliosis, Nervous System

Interventions: Biological: VLA15 without Alum
Biological: VLA15 with Alum

First Posted Date: 2017-01-04

Last Posted Date: 2023-04-05

Lead Sponsor: Pfizer

Target Recruit Count: 179

Registration Number: NCT03010228

Locations: 🇧🇪
University Hospital Ghent, Ghent, Belgium
🇺🇸
Celerion, Inc, Lincoln, Nebraska, United States
🇺🇸
eStudySite, La Mesa, California, United States

and more 2 locations

A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA

Phase 3

Completed

Conditions: Arthritis Juvenile Idiopathic

First Posted Date: 2016-12-22

Last Posted Date: 2025-06-03

Lead Sponsor: Pfizer

Target Recruit Count: 100

Registration Number: NCT03000439

Locations: 🇩🇪
St. Josef-Stift Sendenhorst, Sendenhorst, Germany
🇭🇺
Semmelweis Egyetem, Budapest, Hungary
🇮🇳
Nirmal Hospital Pvt Ltd, Surat, Gujarat, India

and more 47 locations

Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: PF-06650833
Drug: Placebo
Drug: Tofacitinib

First Posted Date: 2016-12-19

Last Posted Date: 2020-02-27

Lead Sponsor: Pfizer

Target Recruit Count: 269

Registration Number: NCT02996500

Locations: 🇺🇸
Arthritis & Rheumatic Care Center, South Miami, Florida, United States
🇺🇸
Medical Associates of North Georgia, Canton, Georgia, United States
🇺🇸
Millennium Research, Ormond Beach, Florida, United States

and more 96 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy